The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
In this study, we conducted a meta-analysis to assess the efficacy and safety of teprotumumab in treating thyroid eye disease. We searched the Cochrane Library, PubMed, and Embase databases from inception to May 25, 2022, and included all randomized controlled trials. Odds ratios (ORs) were calculat...
Saved in:
| Main Authors: | Fei Lin, Qiu’e Yao, Bin Yu, Zehui Deng, Jingyue Qiu, Rong He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | International Journal of Clinical Practice |
| Online Access: | http://dx.doi.org/10.1155/2023/6638089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An Update on Medical Management of Thyroid Eye Disease with Insights on Teprotumumab
by: Smriti Dabas, et al.
Published: (2023-07-01) -
A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context
by: Yuji Hiromatsu, et al.
Published: (2025-02-01) -
Teprotumumab in the management of thyroid eye disease mechanistic insights and adverse reactions: a comprehensive review
by: Zhibin Xu, et al.
Published: (2025-05-01) -
Spectral-domain optical coherence tomography imaging findings in patients receiving teprotumumab for thyroid eye disease
by: Timothy Truong, et al.
Published: (2025-06-01) -
Resolution of Thyroid Acropachy in a Patient Treated With Teprotumumab: A Case Report and Review of Mechanisms
by: Soumya Chatterjee
Published: (2025-01-01)